CYP19A1 and breast carcinoma: Furthermore, the retained sensitivity but decreased efficacy of anti-estrogens in preclinical ESR1 mutant models suggests that the standard dose of anti-estrogens such as tamoxifen often used in the aromatase inhibitor-refractory setting may be inadequate in ESR1 mutant breast cancers.